基于UPLC-Q-Orbitrap/MS技术对非酒精性脂肪性肝病患者的血清脂质组学研究

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1177 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the characteristics of lipid metabolism in patients with non-alcoholic fatty liver disease (NAFLD) based on serum lipidomics. Methods A total of 30 NAFLD patients and 30 normal people in Putuo District Central Hospital of Shanghai from January 2020 to January 2021 were included in the study. UPLC-Q-Orbitrap / MS was used for lipidomics analysis of serum of two groups. Principal component analysis and orthogonal partial least squares discriminant analysis were used for multidimensional statistical analysis of data, metabolites with VIP value >1 and P < 0.05 were used as differential lipid biomarkers. Results There were statistically significant differences in body mass index, alkaline phosphatase, total protein, cholinesterase, urea, and triglyceride between two groups (P < 0.05). There were no significant differences in age, gender, total bilirubin, direct bilirubin, albumin, γ-glutamic transpeptidase, alanine aminotransferase, aspartate aminotransferase, total bile acid, creatinine, uric acid, glomerular filtration rate, high density lipoprotein cholesterol, low density lipoprotein cholesterol, and total cholesterol between two groups (P > 0.05). A total of 181 differential lipid biomarkers were screened, including triglyceride, diglyceride, sphingomyelin, phosphatidylserine, phosphatidylcholines, phosphatidylinositols, phosphatidylglycerides, phosphatidylethanolamines, O-acyl-ω-hydroxy fatty acid, monoglyceride, lysophosphatidylinositol, lysophosphatidylglyceride, lysophosphatidylethanolamine, lysoph- osphatidylcholine, and ceramide. Conclusion Lipid metabolism in NAFLD patients is significantly different from that in the normal population, 181 lipid biomarkers screened in this study can be used as potential new targets for NAFLD.

Key words： Non-alcoholic fatty liver disease Lipido- mics；UPLC-Q-Orbitrap / MS

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TIAN Jiyun DU Shengnan GAO Jingjing YUAN Yifu CAO Qin▲ JIANG Yuanye▲

Cite this article:

TIAN Jiyun DU Shengnan GAO Jingjing YUAN Yifu CAO Qin▲ JIANG Yuanye▲. Study on serum lipidomics of non-alcoholic fatty liver disease patients based on UPLC-Q-Orbitrap / MS technology[J]. 中国医药导报, 2022, 19(19): 5-11.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I19/5

[1] lmakki E，Aqeely H，Bani I，et al. Nonalcoholic Fatty Liver Diseas（NAFLD）in Saudi Patients with T2DM in Jazan Region：Prevalence and Associated Factors [J]. Br J Med Med Res，2015，5（7）：872-879.
[2] Day CP，James OF. Steatohepatitis：a tale of two“hits”？[J]. Gastroenterology，1998，114（4）：842-845.
[3] Castera L，Friedrich-Rust M，Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease [J]. Gastroenterology，2019，156（5）：1264-1281.
[4] Jarvis H，Craig D，Barker R，et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease（NAFLD）：A systematic review and meta-analysis of population-based observational studies [J]. PLoS Med，2020，17（4）：e1003100.
[5] Stols-Gon?觭alves D，Hovingh GK，Nieuwdorp M，et al. NAFLD and Atherosclerosis：Two Sides of the Same Dysmetabolic Coin？ [J]. Trends Endocrinol Metab，2019，30（12）：891-902.
[6] Han X，Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry：a bridge to lipidomics [J]. J Lipid Res，2003，44（6）：1071-1079.
[7] Lagarde M，Gélo?觕n A，Record M，et al. Lipidomics is emerging [J]. Biochim Biophys Acta，2003，1634（3）：61.
[8] Masoodi M，Gastaldelli A，Hy?觟tyl?覿inen T，et al. Metabolomics and lipidomics in NAFLD biomarkers and non-invasived iagnostictests [J]. Nat Rev Gastroenterol Hepatol，2021，18（12）：835-856.
[9] 李军祥，陈誩，王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2017，25（11）：805-811.
[10] 张声生，李军祥.非酒精性脂肪性肝病中医诊疗专家共识意见（2017）[J].临床肝胆病杂志，2017，33（12）：2270-2274.
[11] Tirosh O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression [J]. Oxid Med Cell Longev，2018：2548154.
[12] Feldstein AE，Lopez R，Tamimi TA，et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]. J Lipid Res，2010，51（10）：3046-3054.
[13] Pagadala M，Kasumov T，McCullough AJ，et al. Role of ceramides in nonalcoholic fatty liver disease [J]. Trends Endocrinol Metab，2012，23（8）：365-371.
[14] Puri P，Wiest MM，Cheung O，et al. The plasma lipidomic signature of nonalcoholic steatohepatitis [J]. Hepatology，2009，50（6）：1827-1838.
[15] Mendez-Sanchez N，Cruz-Ramon VC，Ramirez-Perez OL，et al. New spects of Lipotoxicity in Nonalcoholic Steatohepatitis [J]. Int J Mol Sci，2018，19（7）：2034.
[16] Puri P，Baillie RA，Wiest MM，et al. A lipidomic analysis of nonalcoholic fatty liver disease [J]. Hepatology，2007， 46（4）：1081-1090.
[17] Gorden DL，Ivanova PT，Myers DS，et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease；comparison to a murine model [J]. PLoS One，2011，6（8）：e22775.
[18] Anjani K，Lhomme M，Sokolovska N，et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity [J]. J Hepatol，2015，62（4）：905-912.
[19] 张有江，徐勤，袁飞.脂肪肝患者血脂及胆碱酯酶测定的临床意义[J].实验与检验医学，2008，26（5）：5557-5582.
[20] Hu Y，He W，Huang Y，et al. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD [J]. Hepatology，2021，74（5）：2508-2525.
[21] 杨萍，李秋芳.血清AKP、γ-GT、甲胎蛋白在原发性肝癌患者介入治疗前后的变化及意义[J].中国卫生工程学，2021，20（1）：160-161.
[22] Chan AW，Chan SL，Mo FK，et al. Albumin-to-alkaline phosphatase ratio：a novel prognostic indexf or hepatocellular carcinoma [J]. DisMarkers，2015，2015：564057.
[23] Lemaitre RN，Yu C，Hoofnagle A，et al. Circulating Sphingolipids，Insulin，HOMA-IR，and HOMA-B：The Strong Heart Family Study [J]. Diabetes，2018，67（8）：1663-1672.
[24] 杨蕊旭，胡春秀，宓余强，等.非酒精性脂肪性肝病患者血清脂质组学研究[J].中华肝脏病杂志，2017，25（2）：122-127.
[25] Tu LN，Showalter MR，Cajka T，et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice [J]. Sci Rep，2017，27（1）：6120.
[26] Casta?觡o D，Rattanasopa C，Monteiro-Cardoso VF，et al. Lipid efflux mechanisms，relation to disease and potential therapeutic aspects [J]. Adv Drug Deliv Rev，2020，159：54-93.